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The 2G12 mAb inhibits the infection of HIV-1 laboratory-adapted viruses at 50% inhibitory concentrations (IC50) ranging from 0.02 to 0.2 μg/
ml when evaluated in different cell-types. However, isolates from various HIV-1 subtypes (such as clade C, D, A/E, F and group O) were not
inhibited by 2G12 mAb (IC50 >20 μg/ml). 2G12 mAb pressure in HIV-1 IIIB- and NL4.3-infected T cell cultures selected for resistant viruses
containing only few (1 to 3 N-glycosylation) deletions in gp120. The 2G12-resistant viruses keep their full sensitivity to various mannose-specific
lectins and other known HIV entry inhibitors. Moreover, we observed that the NL4.3-2G12-resistant virus, with the N295K mutation in gp120,
became significantly more sensitive to several mannose-specific lectins. This is, to our knowledge, the first report showing that a resistant virus
generated in vitro against a neutralizing mAb and containing a mutation in gp120, has increased sensitivity to another class of HIV entry
inhibitors.
© 2006 Elsevier Inc. All rights reserved.Keywords: 2G12; Resistance; Glycosylation; gp120; Mannose-specific lectinsIntroduction
The necessity to lower or halt the world-wide spread of HIV
infection is a serious problem that needs to be urgently
addressed. The most obvious approach to combat the ongoing
HIV pandemic is through the development of an effective
vaccine. However, HIV vaccine design has faced numerous
difficulties and especially the lacking of broadly neutralizing
antibodies is a major drawback challenge (Burton et al., 1994;
Burton and Montefiori, 1997; Connor et al., 1998; D'Souza
et al., 1997; Kostrikis et al., 1996; Moog et al., 1997; Moore
et al., 1996; Moulard et al., 2002; Parker et al., 2001; Parren
et al., 1999; Roben et al., 1994).
So far, only very few broadly neutralizing monoclonal
antibodies (mAbs) have been isolated from HIV-positive
individuals (Burton et al., 1994; Burton, 1997; Moulard et al.,Abbreviations: CV-N, cyanovirin; HHA, Hippeastrum hybrid agglutinin;
GNA, Galanthus nivalis agglutinin; CA, Cymbidium agglutinin; mAb,
monoclonal antibody.
⁎ Corresponding author. Fax: +32 16 337340.
E-mail address: Dominique.schols@rega.kuleuven.be (D. Schols).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.10.0272002; Parker et al., 2001; Roben et al., 1994; Sattentau and
Moore, 1995; Scanlan et al., 2002; Stiegler et al., 2001; Zwick
et al., 2001a, 2001b) and have been shown to protect against
HIV-1 infection in vitro and in animal models in vivo (Baba
et al., 2000; Mascola et al., 1999, 2000a, 2000b; Shibata et al.,
1999). One of these antibodies, 2G12 mAb, is directed against
an epitope at gp120 that lies around the stem of the V3 loop and
the V4 variable region. Interestingly, the recognized epitope of
2G12 mAb on gp120 contains high-mannose type glycans at
several N-glycosylation sites (Calarese et al., 2003, 2005;
Kunert et al., 1998; Kwong et al., 1998, 2000a, 2000b; Scanlan
et al., 2002; Trkola et al., 1996; Wyatt et al., 1998; Wyatt and
Sodroski, 1998; Zwick et al., 2001a). This is very unusual
because glycosylated peptide epitopes often contain micro-
heterogenic carbohydrates causing dilution of a single antigenic
response.
The mAb 2G12 is unique among the studied antibodies in
that it appears like a tightly packed dimer formed by an
unprecedented VH domain swapping (Calarese et al., 2003). It
has been described that 2G12 mAb broadly and potently
neutralized the majority of clade B primary and T cell line-
adapted strains and that it also has neutralizing activity against
295D. Huskens et al. / Virology 360 (2007) 294–304viruses of clade A and other subtypes (Trkola et al., 1995,
1996). Some studies showed that 73% of clade B isolates were
susceptible to neutralization with 2G12 mAb (Burton et al.,
2004). Other studies showed that only 53%, 40% or 41% of the
HIV-1 isolates were susceptible to 2G12 mAb (Binley et al.,
2004; Mehandru et al., 2004; Rusert et al., 2005).
Poignard et al. (1999) evaluated high serum concentrations
of a cocktail of the monoclonal antibodies 2G12, B12 and 2F5
for treatment of established HIV-1 infection in hu-PBL-SCID
mice. They observed little sustained effect on viral load.
Neutralization escape occurred after a few days of treatment.
The potency of 2G12 mAb (in combination with 2 other
neutralizing mAbs 2F5 and 4E10) was recently evaluated in
HIV-1-infected individuals. There was a delay in viral rebound
in some of the patients (2 out of 8) and escape mutant analysis
showed that the activity of 2G12 mAb was crucial for the in
vivo effects of the neutralizing antibody cocktail (Trkola et al.,
2005).
Trkola et al. (1996) and Scanlan et al. (2002) investigated
mutations on gp120 at N295, N332, N339, N386 and N392 by
N→A substitutions and demonstrated a marked decreased
affinity for 2G12 mAb binding. Clade C isolates also do not
react with 2G12 mAb (Binley et al., 2004; Chen et al., 2005),
but reintroduction of a single glycosylation site at N295
recovered 2G12 mAb binding ability (Chen et al., 2005). Thus,
whereas N339 and N386 proved less critical for 2G12 mAb
binding, and may rather play an indirect role in maintaining the
correct epitope conformation, N295 and N332 were described
to be crucial for 2G12 mAb binding (Sanders et al., 2002;
Scanlan et al., 2002; Chen et al., 2005).
The extensive activity profile of plant lectins and CV-N
against numerous isolates and clades of HIV-1 and other
lentiviruses supports the potential broad utility of these proteins
as a microbicide to prevent the sexual transmission of HIV.
Indeed, CV-N is shown to inhibit HIV infections in a vaginal
transmission model (Tsai et al., 2003, 2004), suggesting that
CV-N, but also mannose- and N-acetylglucosamine-specific
plant lectins (Balzarini et al., 1991, 1992, 2004a, 2005a), are
good candidates for testing in humans as a potential anti-HIV
topical microbicide.Table 1
Sensitivity profile of HIV-1 wild-type and 2G12-resistant strains against viral entry
Agent IC50
a (μg/ml)
HIV-1 IIIB HIV-1 IIIB-2G12res (#3) b Fold resistance c
2G12 mAb 1.4±0.4 >50 [>36]
HHA 0.29±0.19 0.55±0.35 [2]
GNA 0.48±0.28 0.65±0.21 [1]
CA 0.53±0.23 5.0±1.4 [9]
CV-N 0.038±0.010 0.13±0.04 [4]
DS-5000 0.33±0.12 1.25±0.35 [4]
AMD3100 0.05±0.03 0.2±0.1 [4]
T-20 0.010±0.002 0.04±0.01 [4]
a 50% Inhibitory concentration, or drug concentration required to inhibit virus-ind
strains by 50%.
b Comparable values were obtained with 2 other HIV-1 IIIB viruses that were gen
c Values between brackets represent the degree (fold) of resistance or sensitivity
Values are mean±standard deviation from 3 to 4 separate experiments.Here, we examined the antiviral activity of 2G12 mAb
against various viruses, and examined the resistance profile of 2
HIV-1 strains (IIIB and NL4.3) that were exposed to 2G12
mAb. The nucleotide sequence of the gp120 envelope
glycoprotein was characterized and the glycosylation patterns
were derived thereof. Subsequently, the sensitivity to HIVentry
inhibitors, with special emphasis on mannose-specific lectins
such as CV-N, CA, HHA and GNA (Balzarini et al., 1991,
1992, 2004a, 2004b, 2005a, 2005b; Bewley, 2001; Bolmstedt
et al., 2001; Botos et al., 2002; Boyd et al., 1997; Esser et al.,
1999; Pashov et al., 2005; Tsai et al., 2003, 2004; Turville et al.,
2005) was examined in detail.
Results
Antiviral activity of 2G12 mAb in cell cultures
The mAb 2G12, the α(1,3)- and/or α(1,6)-mannose-specific
plant lectins GNA, HHA and CA, the α(1,2)-mannose-specific
procaryotic lectin CV-N (Bolmstedt et al., 2001; Boyd et al.,
1997), the polyanionic HIV adsorption inhibitor DS-5000 (Ito
et al., 1987), the gp41 fusion entry inhibitor T-20 (Wild et al.,
1994) and the CXCR4 antagonist AMD3100 (Schols et al., 1997)
were evaluated for their antiviral activity against HIV-1 IIIB in
CEM cells and against HIV-1 NL4.3 in MT-4 cells (Table 1). The
2G12 mAb proved to exert comparable antiviral activity against
HIV-1 IIIB and NL4.3, a phenomenon which was also observed
with T-20 and CA (Table 1). An IC50 of 0.26μg/ml for 2G12mAb
was obtained against the clinical HIV-1 HE strain in MT-4 cells.
Somewhat surprisingly was the observation that no activity of
2G12 mAb (IC50 >50 μg/ml) was observed when evaluated
against several other HIV-1 laboratory strains of clade B such as
RF, NDK and MN. AMD3100 and the mannose-specific lectins
HHA and GNA showed a better antiviral activity against NL4.3
compared to IIIB, however, for CV-N and DS-5000 this was the
opposite (Table 1).
Then we examined 2G12 mAb for its inhibitory potential
against a wide variety of HIV-1 clade isolates in PBMCs
(Table 2). Here also, 2G12 mAb showed variable antiviral
activity from a strong inhibitory activity (IC50: 0.04 μg/ml) toinhibitors
HIV-1 NL4.3 HIV-1 NL4.3-2G12res Fold resistance/sensitivityc
0.98±0.42 >50 [>50]
0.092±0.033 0.006±0.001 [15]*
0.083±0.026 0.017±0.012 [5]*
0.21±0.05 0.073±0.017 [3]*
0.74±0.89 0.14±0.07 [5]*
2.32±0.18 1.62±0.43 [1]
0.003±0.001 0.002±0.001 [1]
0.012±0.002 0.009±0.004 [1]
uced CPE in CEM cells for HIV-1 IIIB strains or MT-4 cells for HIV-1 NL4.3
erated in independent experiments under 2G12 mAb pressure (up to 50 μg/ml).
(indicated by an asterisk) of the test compounds, compared to wild-type virus.
Table 2
Antiviral activity of 2G12 mAb and mannose-binding proteins in PBMCs against a variety of HIV-1 clade isolates, laboratory HIV-1 strains and HIV-2
Agent IC50
a (μg/ml)
HIV-1 clades (with co-receptor preference) HIV-2 HIV-1 laboratory strains
A B C D A/E F G O
UG273 US2 ETH2220 UG270 ID12 BZ163 BCF-DIOUM BCF06 BV-5061W IIIB NL4.3 BaL
(R5) (R5) (R5) (X4) (R5) (R5) (R5) (X4) (X4) (X4) (X4) (R5)
2G12 mAb 0.018 0.04 >20 >20 >20 >20 >20 >20 >20 0.18 0.08 0.09
HHA 29 5.4 44 4.9 12 4.6 41 1.2 8.9 1.1 0.36 6
GNA 27 17 ≥100 >20 19 25 ≥100 1.9 9.5 0.33 1.4 6.5
CA 5.5 2.9 12 5.3 1.2 6.3 9.2 3.3 1.1 0.36 0.22 2.4
CV-N 1.4 0.42 1.8 0.32 1.1 1.1 0.85 0.15 0.36 0.01 0.15 1.8
a 50% inhibitory concentration, or compound concentration required to inhibit viral p24 (for HIV-1) or p27 (for HIV-2) production by 50%.
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observed against the HIV-2 strains BV-5061W, ROD and EHO
or SIVmac251 (Table 2 and data not shown). Whereas the anti-
viral activity of CV-N only ranged between 0.15 and 1.8 μg/ml,
the mannose-specific plant lectins showed greater variability
in their virus-suppressive potential [i.e., 1.2 μg/ml (group O)
to ≥100 μg/ml (clade G)] depending on the nature of the
virus clade (Table 2).
Inhibition of 2G12 mAb binding to gp120 on HIV-infected
MT-4 cells
Binding of CV-N to soluble gp120 inhibited subsequent
interaction of 2G12 mAb with gp120, as shown previously by
others (Boyd et al., 1997; Esser et al., 1999) using rgp120
coated on microtiter plates and measuring optical density. Here,
we determined the IC50 value of CV-N to inhibit 2G12 mAb
binding on HIV-1-infected MT-4 cells by flow cytometry
(Fig. 1). The IC50 values of CV-N were 0.21 μg/ml for both
HIV-1 IIIB and NDK and 0.20 μg/ml for HIV-1 MN. Also the
mannose-specific plant lectins HHA and GNA inhibited the
binding of 2G12 mAb with IC50 values in the lower microgram
range (Fig. 1). HHA had IC50 values of 2.50 μg/ml, 1.46 μg/ml
and 1.86 μg/ml and GNA had IC50 values of 4.76 μg/ml,
4.02 μg/ml and 1.08 μg/ml when using HIV-1 IIIB, MN and
NDK, respectively. Interestingly, although the 2G12 staining of
MN and NDK gp120 was comparable to that of HIV-1 NL4.3
and HE (Fig. 2), viral infection of MN and NDK was not
inhibited by 2G12 mAb. We also performed staining with an
anti-gp120 V3 loop mAb (9205) on these HIV-1 NL4.3-, HE-,
MN- and NDK-infected cells. As can be seen in Fig. 2, 9205
mAb did not recognize HE- and NDK-infected cells and
subsequently had also no antiviral activity against these two
HIV-1 strains. However, although staining of 9205 mAb on
HIV-1 MN-infected cells was less pronounced compared to the
HIV-1 NL4.3-infected cells, the antiviral activity was not much
different (IC50 was 0.10 μg/ml for HIV-1 NL4.3 and 0.16 μg/ml
for HIV-1 MN).
In contrast, all these virus strains were equally well inhibited
by the mannose-specific lectins HHA, GNA, CA and CV-N
(Table 1; Balzarini et al., 2004a, 2004b, 2005a, 2005b; and
unpublished data).Determination of mutations in the genome of the
2G12-resistant virus isolates
The 2G12-resistant HIV-1 strains were analyzed for amino
acid changes in the genome. When all amino acid changes were
considered in gp160 of the HIV-1 NL4.3-2G12res (NL4.3-
2G12-resistant) virus, only one specific and pure mutation
occurred at an N-glycosylated asparagine, N295K. In addition,
the mutation T297T/I was observed, a mutation in the T of the
glycosylation motif which will also affect glycosylation of the
gp120. For the NL4.3-2G12res virus, additional mutations were
found at I194I/V, V270V/I and Q310H.
For the three IIIB-2G12res viruses, only mutations were
found that indirectly affected the gp120 N-glycosylation motifs,
i.e., mutation of T or S in the glycosylation motif. In these
resistant HIV-1 IIIB viruses, mixtures of the wild-type and the
mutated amino acids were noticed but no asparagines were
directly affected. In all three HIV-1 IIIB-2G12res viruses was
found the mutation T394[T, I]. HIV-1 IIIB-2G12res #1 and #3
had also the mutation T297[T, I] and T408[T, I] was only found
in HIV-1 IIIB-2G12res #1.
Cross-resistance of 2G12-resistant viruses to other compounds
We also examined the effect of the mannose-specific lectins,
the polyanion DS-5000, the CXCR4 antagonist AMD3100 and
the gp41 fusion entry inhibitor T-20 on the replication of the
wild-type virus and the 2G12res viruses (Table 1). Not only DS-
5000, AMD3100 and T-20 kept their suppressive effects to the
2G12res strains, but also the mannose-specific lectins. Remark-
ably, the mannose-specific lectins were more inhibitory against
the HIV-1 NL4.3-2G12res virus compared to the wild-type
virus (especially HHA: ∼15-fold), whereas this phenomenon
was not observed against the 2G12res viruses of the HIV-1 IIIB
strain. The 9205 mAb recognizing the V3 loop of gp120 was
equally active against the wild-type and the 2G12res viruses.
Also, the anti-CD4 mAb (RPA-T4) and soluble CD4 were
equally active against the wild-type and the 2G12res viruses
(data not shown). The wild-type virus that had been grown in
MT-4 cells in parallel with the 2G12res virus (but in the absence
of 2G12 mAb) was as sensitive as the original virus stock to
2G12 mAb (IC50: 0.26 μg/ml).
Fig. 1. Inhibition of the binding of 2G12 mAb to HIV-1-infected MT-4 cells in the presence of GNA, HHA and CV-N. MT-4 cells infected with HIV-1 strains IIIB (left
panel), MN (middle panel) and NDK (right panel), were incubated with 2G12 mAb in the absence (red histograms) or presence of different concentrations of GNA
(green histograms), HHA (orange histograms) and CV-N (light blue). The dark blue histograms show the background fluorescence. The mean fluorescence intensity
(MFI) values are indicated in each histogram.
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Fig. 2. Staining of 2G12 mAb and 9205 mAb on MT-4 cells 4 days after
infection with HIV-1 strain NL4.3, HE, MN, and NDK. MFI of the background
fluorescence (blue histograms), for the 2G12 mAb binding (red histograms) and
for the 9205 mAb binding (green histograms) are indicated.
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When HIV-1 NL4.3-infected MT-4 cells were stained with
the 2G12 mAb more than 99% of the cells were positive 3–
4 days after infection (MFI: 28.96) (Fig. 3). However, when the
staining was done on the HIV-1 NL4.3-2G12res-infected MT-4
cells, the MFI value decreased till 7.87 (73% decrease) (Fig. 3).
As a control, staining with the 9205 mAb was included, a mAb
recognizing the tip of the V3 loop of gp120 (Skinner et al.,
1988). On wild-type and NL4.3-2G12res-infected MT-4 cells,
the 9205 mAb staining was comparable demonstrating that on
both cells gp120 was present in equal amounts (Fig. 3). When
HIV-1 IIIB-infected MT-4 cells were stained with 2G12 mAb,
the same fluorescence pattern was obtained as for HIV-1 NL4.3.
When the staining was done on the MT-4 HIV-1 IIIB-2G12res
(#1)-infected cells, the MFI decreased from 32.28 to 15.39
(∼50% decrease) (Fig. 3). Comparable values were obtained for
the 2 other HIV-1 IIIB-2G12res viruses (MFI of 16.31 and
23.59 for IIIB-2G12res #2 and #3, respectively). In contrast, no
staining at all of 2G12 mAb was observed on HIV-1 IIIB-HHAres and on HIV-1 IIIB-GNAres viruses that were
previously selected in the presence of HHA and GNA,
respectively (Fig. 3). The MFI values of 2G12 mAb of the
two mannose-specific lectin-resistant viruses decreased towards
the level of the background staining. This observation is in line
with earlier reports showing that none of these plant lectin-
resistant viruses showed sensitivity to 2G12 mAb at a
concentration up to 100 μg/ml (Balzarini et al., 2004b,
2005b). In contrast to the staining with the 2G12 mAb, staining
with 9205 mAb was in all the virus-infected cells equally and
consistently positive (Fig. 3, right panels).
Discussion
Many reports have documented the importance of glycosyla-
tion for infectivity and pathogenesis of HIV (Balzarini et al.,
2005a; Balzarini, 2005; Turville et al., 2001; Wyatt et al., 1993).
There may be about 20–29 potential N-linked glycosylation
sites distributed on gp120 and the carbohydrate content
constitutes about 50% of the mass of gp120 (Leonard et al.,
1990). It was proposed that these carbohydrates act as a shield
to protect the virion from the humoral immune response (Wyatt
et al., 1998). Thus, compounds interacting with the carbohy-
drate domains on the virion envelope might provide effective
ways to inhibit viral infection.
The 2G12 mAb interacts with very specific, highly
conserved glycosylation sites on gp120 (i.e., N-295, N-332
and N-392), and its binding to HIV-1 gp120 is further
influenced by the presence of the N-339 and N-386 glycans
(Scanlan et al., 2002; Zhu et al., 2000). Here, we also observed
that the single mutation of N295K rendered the NL4.3 virus
insensitive to 2G12 mAb. Also the three 2G12-resistant HIV-1
IIIB strains showed the T394T/I (partial) mutation, deleting the
N392 glycan. The N-glycosylation sites that were deleted under
2G12 mAb pressure were mapped on the three-dimensional
structure of gp120 determined by Kwong et al. (1998) and
appear to be clustered (Fig. 4, left panel). In contrast, the
multiple deleted N-glycosylation sites appear to be scattered
under the pressure of HHA and GNA (Fig. 4, right panel). Thus,
whereas a large number of N-glycan deletions are required to
afford a moderate decrease of mannose-specific lectins
sensitivity against the mutated virus strains (Balzarini et al.,
2004b, 2005b), one glycan deletion was already sufficient for
2G12 mAb to completely lose its antiviral activity. These
observations explain why “broadly” neutralizing antibodies,
such as 2G12 mAb, quickly generate resistant viruses, a
characteristic which is obviously due to their specific binding
interaction with gp120. Also, binding of 2G12 mAb to gp120
may be necessary, but not sufficient to exert its antiviral activity.
As was shown in Fig. 2, 2G12 mAb binding of MN and NDK
gp120 was comparable to that of NL4.3, HE and IIIB, but viral
infection of MN and NDK was not at all inhibited by 2G12
mAb. It has been reported for another neutralizing mAb, 2F5,
that high affinity binding by itself is not sufficient to be
neutralizing, even when the epitope is at a critical position (Ou
et al., 2006). When the HIV-1 NL4.3, NDK, MN and RF gp120
envelope was examined for the presence (or absence) of the
Fig. 3. Staining of 2G12 mAb (left panel) and 9205 mAb (right panel) on MT-4 cells 3–4 days after infection with HIV-1 NL4.3 and NL4.3-2G12res virus HIV-1 IIIB,
IIIB-2G12res, IIIB-GNAres and IIIB-HHAres. The MFI of the background fluorescence (blue histograms), for the 2G12 mAb (red histograms) and for the 9205 mAb
(green histograms) are indicated.
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could be made to explain the inactivity of 2G12 mAb against
several of these HIV-1 strains in cell culture. In fact,
glycosylated N295, N392 and N386 were invariantly present
in the wild-type HIV-1 IIIB, MN, NDK, NL4.3 and RF strains.
However, N332 and N339 were absent in the NDK strain. Also
the N406 glycan is lacking in HIV-1 NDK but not in the other
HIV-1 strains. These observations cannot explain the inactivityof 2G12 mAb against the HIV-1 (MN or RF) strains. Similar
observations have been made for several HIV-1 clade isolates.
Clearly, there is a more complex situation ongoing, in which the
genetic background of the gp120 envelope HIV-1 IIIB may also
be important to determine the eventual phenotype of glycan
deletions against 2G12 mAb. It also cannot be excluded that
mutations in gp120 at amino acid sites that are not part of the
glycosylation motifs, can afford subtle conformational changes,
Fig. 4. Ribbon diagrams showing the N-glycosylation site mutations (red balls) in gp120 of 2G12 mAb-exposed HIV-1 strains (left panel, 3 mutations) and the
mannose-binding plant lectin-exposed HIV-1 strains (right panel, 14 mutations). The left panel shows the 24 putative glycosylation sites represented by yellow circles
and their accompanying amino acid number. The red circles indicate the deleted N-glycosylation sites that appear under 2G12 mAb in the 4 different HIV-1 isolates.
The right panel shows the mutated N-glycosylation sites in gp120 of a variety of HIV-1 strains grown in the presence of the mannose-specific lectins HHA and GNA.
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the 2G12 mAb.
Resistance studies performed earlier in 2 subtype B viruses
(92BR30 and S2/05) with 2G12 mAb showed that in none of
the escape viruses a change in the N residues was found, except
a change of N386K in one virus (Nakowitsch et al., 2005).
Remarkably, the same authors found that HIV-1 IIIB was
insensitive to 2G12 mAb inhibition, whereas Trkola et al.
(1996) and our data showed that HIV-1 IIIB is quite sensitive to
2G12 mAb, adding even more complexity to the neutralizing
potential of 2G12 mAb.
All five N positions of gp120 involved in 2G12 mAb binding
were also found to be mutated in one or several of our plant
lectin-resistant mutant virus strains (Balzarini et al., 2004b,
2005b). As it was also shown that the plant lectins competed
with 2G12 mAb for the glycan interaction sites and prevents
2G12 mAb binding to this epitope on gp120 [whereas prior
binding of 2G12 mAb to gp120 did not block subsequent
binding of fluorescent GNA (data not shown)], it is logic to
assume that these lectins may recognize this region of the gp120
molecule as well. These conclusions are also in line with the
complete resistance of the mannose-specific lectin virus strains
against the mAb 2G12.Table 3
Presence of 2G12-related N-glycans in different HIV-1 strains
2G12-related
N-glycan recognition a
HIV-1 strain
IIIB MN NL4.3 NDK RF
N295a + + + + +
N332a + + + − +
N392a + + + + +
N339a + + + − +
N386a + + + + +
N406 b + + + − +
a N-glycans that play a direct (N295, N332, N392) or indirect (N339, N386)
role in the recognition of gp120 by 2G12 mAb (according to Zhu et al., 2000 and
Scanlan et al., 2002).
b N-glycan deletion observed to occur under selective pressure of 2G12 mAb
against HIV-1 IIIB in CEM cell cultures.Remarkable is the observation that the mannose-specific
lectin HHA clearly gained more activity against the HIV-1
NL4.3-2G12res virus. This enhanced activity is also, although
less, seen with the other mannose-specific lectins (GNA, CA
and CV-N), but not with DS-5000, AMD3100, T-20 (Table 1),
soluble CD4 or anti-CD4 mAb (data not shown). Enhanced
activity (10-fold) was also observed with the mannose-specific
plant lectin NPA (obtained from Narcissus pseudonarcissus),
but not with the N-acetylglucosamine-binding protein from
Urtica dioica (UDA) or with the non-peptidic carbohydrate
binding agent pradimycin-A (data not shown). The enhanced
activity was not only seen in MT-4 cells, but also in another T
cell line (SUPT-1) and in PBMCs demonstrating that the
enhanced antiviral effect is consistent and not due to the target
cell used in our assays. How can mutations induced by a mAb
and directed against the gp120 of HIV-1 NL4.3 enhances the
antiviral activity of the mannose-specific lectins? Very likely the
increased sensitivity towards HHA, GNA, CA and CV-N is not
just due to the single N295 mutation, because in subtype clade C
viruses the N295 glycosylation is consistently missing and no
increase in antiviral activity of the mannose-specific lectins is
observed (Table 2; Balzarini et al., 2005a, 2005b). Thus, the
mechanism behind this phenomenon is more complex. We
therefore performed several additional binding experiments on
the 2G12-resistant NL4.3 virus. We observed that the binding of
2G12 mAb was significantly better inhibited by HHA and GNA
in 2G12 mAb-resistant HIV-1 NL4.3 compared to the wild-type
NL4.3 virus. We obtained IC50 values for HHA and GNA to
inhibit 2G12 mAb binding on NL4.3 WT-infected cells of
0.89 μg/ml and 1.26 μg/ml, respectively, whereas on the 2G12
mAb-resistant HIV-1 NL4.3-infected cells this was 0.038 μg/ml
(23-fold increase) and 0.064 μg/ml (20-fold increase). This
observation confirms that, although one N-glycosylation site is
missing, and mannose-specific lectins are expected to become
less active, these agents showed an enhanced inhibition of viral
infection. It is possible that in the envelope of the N-295 glycan
mutated NL4.3 virus, various other mannose oligomers located
on other glycan positions became better accessible to these
relatively large tetrameric proteins (4×12.5 kDa). Reeves et al.
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remained sensitive to other entry inhibitors such as anti-CD4
mAb, the CXCR4 antagonist AMD3100 and the CCR5
antagonist TAK-779. However, the authors also reported that
some (but not all) enfuvirtide-resistant viruses showed an
increased sensitivity to a subset of neutralizing mAbs such as
B12, 2F5 and 4E10. They showed that mutations in the HR1
region of gp41 resulted in slower membrane fusion kinetics and
it was therefore suggested that this could be a reason why some
of the mAbs could have an enhanced neutralizing capacity.
However, we observed that virus-induced CPE or viral
infectivity as measured by p-24 Ag ELISAs were not
significantly different between the wild-type and the 2G12
mAb-resistant NL4.3 virus.
Our studies now have shown that the “broadly” neutraliz-
ing mAb 2G12 might be endowed with less-broadly
neutralizing properties than originally reported and anticipated
and that it may become much more sensitive to activity loss
due to one or a few amino acid mutations in the HIV envelope
gp120. These properties should be taken into account in the
eventual choice of a carbohydrate-binding agent to be
introduced for HIV treatment or prevention as a microbicidal
agent.
Materials and methods
Test agents
The mannose-specific plant lectins from Galanthus nivalis
(GNA), Hippeastrum hybrid (HHA) and from Cymbidium
hybrid (CA) were derived and purified, as described before
(Van Damme et al., 1987, 1988, 1991, 1994). Cyanovirin
(CV-N) was a kind gift of Dr. Michael Boyd (National Cancer
Institute, Frederick) (Boyd et al., 1997). T-20 (enfuvirtide)
was kindly provided by AIDS Research Alliance (Los
Angeles, CA). The 2G12 mAb was purchased from Polymun
Scientific (Vienna, Austria) and DS-5000 from Sigma (St.
Louis, MO). AMD3100 was a kind gift of Dr. Gary Bridger
(AnorMED, Langley, Canada). The anti-gp120 mAb (9205)
[raised against a synthetic peptide representing amino acids
308 to 322 of the HIV-1 IIIB strain (RIQRGPGRAFVTIGK)]
was purchased from Perkin Elmer (Zaventem, Belgium)
(Skinner et al., 1988).
Primary leukocytes and cell line cultures
Buffy coat preparations from healthy donors were obtained
from the Blood Bank in Leuven, Belgium. Peripheral blood
mononuclear cells (PBMCs) were activated with PHA at 2 μg/
ml (Sigma, Bornem, Belgium) for 3 days and cultured in the
presence of 1 ng/ml IL-2 (Roche Molecular Biochemicals,
Indianapolis, USA). Human T-lymphocytic CEM and SUPT-1
cells were obtained from the American Type Culture Collection
(Rockville, MD) and maintained in RPMI-1640 supplemented
with 10% fetal bovine serum. The MT-4 T cell line was a kind
gift of Dr. L. Montagnier (at that time at the Pasteur Institute,
Paris, France).Viruses
HIV-1 NL4.3, MN, RF, NDK and BaL were obtained
through the AIDS Research and Reference Reagent Program
(Division of AIDS, NIAID, NIH) (Adachi et al., 1986). HIV-1
HE was isolated from a Belgian AIDS patient in 1987 (Pauwels
et al., 1990). Primary clinical isolates representing different
HIV-1 clades and a HIV-2 isolate were all kindly provided by
Dr. L. Lathey from BBI Biotech Research Laboratories, Inc.,
Gaithersburg, MD, and their co-receptor use (R5 or X4) was
determined by us on the astroglioma U87.CD4 cell line
transfected with either CCR5 or CXCR4.
Antiretrovirus assays in T cell lines
The methodology of the anti-HIV assays has been described
previously (Balzarini et al., 2004b, 2005b). The IC50 value
corresponds to the compound concentrations required to
prevent syncytium formation/CPE by 50% in the virus-infected
CEM cell cultures. For determining IC50 in MT-4 cells, MTT/
MTS viability assays were performed, as described previously
(Pauwels et al., 1988).
Antiviral testing of HIV isolates in PBMCs
The PHA-stimulated blasts were seeded at 0.5×106 cells
per well into a 48-well plate containing varying concentra-
tions of compound in medium containing IL-2 (25 U/ml, R &
D Systems Europe, Abingdon, UK). The virus stocks were
added at a final dose of 250 pg HIV-1 or HIV-2. Cell super-
natant was collected at days 9–12 and HIV-1 core Ag in the
culture supernatant was analysed by a p24 Ag ELISA kit
(Perkin Elmer, Zaventem, Belgium). For HIV-2 p27 Ag de-
tection the INNOTEST from Innogenetics (Temse, Belgium)
was used.
Selection of 2G12 mAb-resistant HIV-1 strains
HIV-1 IIIB was added to CEM cell cultures (3–4×105 cells/
ml) in 48-well plates in the presence of 0.5 μg/ml of 2G12 mAb.
Every 3 to 4 days, three independent drug-exposed cultures (#1,
#2, #3) were subcultured by addition of 100 μl of the infected
culture supernatant or 100 μl of the infected cell suspension to
900 μl of a suspension containing 3–4×105 uninfected CEM
cells/ml. An increased drug concentration was given when
extensive cytopathic effect (CPE) was obtained in the previous
cell culture. Under these conditions, 9 to 11 cultivations were
required to reach a concentration of 50 μg/ml 2G12 mAb
that could be added to the three different virus-infected cell
cultures. For HIV-1 NL4.3 resistance studies, MT-4 cells were
infected with HIV-1 NL4.3 in medium containing 2G12 mAb at
0.1 μg/ml. Every 4 or 5 days, the replicating virus was passaged
in fresh uninfected cells in the presence of 2G12 mAb at the
same concentration as in the previous passage or at a two-fold
higher concentration, depending on the amount of CPE
observed. After 6 passages (∼30 days), virus was recovered
that could replicate in the presence of 100 μg/ml of 2G12 mAb,
302 D. Huskens et al. / Virology 360 (2007) 294–304and the induced CPE was similar to that of the wild-type virus
(in absence of 2G12 mAb).
Genotyping of the HIV-1 env region
Proviral DNA or viral RNAwas extracted using the QIAamp
Blood Mini Kit or the QIAamp Viral RNA Mini Kit (Qiagen,
Hilden, Germany). A 3876-bp nucleotide fragment, encom-
passing the gp120 and the gp41 genes, was amplified in an outer
PCR using the Expand High Fidelity PCR System (Roche
Diagnostics, Mannheim, Germany) and outer primers KVL008
and KVL009. A 2346-bp nucleotide fragment of gp120 was
amplified using the inner primers AV317 and AV323. A 2048-
bp nucleotide fragment of gp41 was amplified using the inner
primers AV318 and AV319 (Van Laethem et al., 2005).
Amplification products were separated on a 1% agarose gel
and visualized by ethidium bromide staining. The images were
processed on a videoimager (ImageMaster VDS, Amersham
Biosciences, Roosendaal, The Netherlands). PCR products for
population sequencing were purified with Microspin S-400
(Amersham Biosciences, Roosendaal, The Netherlands).
Sequencing was performed using the BigDye Terminator v3.1
Cycle Sequencing Kit and the reactions were run on an
ABI3100 Genetic Analyzer (Applera, Nieuwerkerk a/d IJssel,
The Netherlands). The sequences were analyzed using
Sequence Analysis version 3.7 and SeqScape version 2.0
(Applera, Nieuwerkerk a/d IJssel, The Netherlands).
Flow cytometric analyses
MT-4 cells were infected with various HIV-1 strains and
analyzed when cytopathicity (CPE) started to occur (3–4 days
after infection). Briefly, after washing with PBS containing 2%
FCS, cells were pre-incubated with or without agents at
different concentrations for 30 min, washed and then incubated
with 2G12 mAb or 9205 mAb for 30 min at 4 °C. Then the cells
were washed and incubated with Rabbit-anti-Human (RaH)
IgG-FITC (DakoCytomation, Denmark) or Goat-anti-mouse
(GaM) IgG-PE (Caltag Laboratories, Burlingame) for 30 min at
4 °C for 2G12 mAb and 9205 mAb, respectively. As a control
for aspecific background staining, cells were stained in parallel
with RaH-IgG-FITC or GaM-IgG-PE only. Then the cells were
washed, fixed with 1% aqueous formaldehyde solution and
analyzed by flow cytometry with a FACScalibur (BD
Biosciences, San Jose, CA). Data were acquired and analyzed
with CellQuest software (BD Biosciences). For the calculations
of the mAb binding, the mean fluorescence intensity (MFI) of
each sample was expressed as percentage of the MFI of control
cells (after subtracting the MFI of the background staining).
Finally, the IC50 values of the compounds were calculated.
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